Imexpharm (IMP), Vietnam's second largest pharmaceutical firm, expects its net profit to rise 6.1 percent to 50 billion dong ($3.1 million) this year, the company report said on Thursday.
Imexpharm, based in the Mekong Delta province of Dong Thap, expected revenues of 530 billion dong ($33 million) this year, up from 525 billion dong last year.
The company, which specialises in antibiotics and vitamins, also said it planned to pay a dividend of 20-25 percent this year, unchanged from 2006.
Imexpharm, the second largest domestic pharmaceutical firm last year in terms of sales after Hau Giang Pharmceutical Co (DHG), said it aimed to raise its domestic market share to 7 percent next year from 4 percent.
Hau Giang Pharmaceutical had first-half revenues of 554.4 billion dong, more than double Imexpharm's.
Imexpharm shares edged up 0.59 percent on Thursday to close at 171,000 dong ($10.5) on the Ho Chi Minh Stock Exchange while shares in Hau Giang Pharmaceutical fell 0.51 percent to 388,000 dong ($24) each.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment